Villas Health: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://villashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil. As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The following claims concerning compounded semaglutide and sildenafil products appear on your website: • “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….” • “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.””

2. 2

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

villashealth.com returned a live site on 2026-08-09 headed "Home Page - Villas Health" with a working catalogue running a promotional code, listing Compounded GLP-1 "begins from $179 your First Month" and Sildenafil "begins from $60.00"-tier products among a wider sexual-health range — both of the product lines the letter names are still sold.

This letter is useful because it shows the same sales technique applied to two very different products, and the second one travels further than the first. Saying compounded semaglutide has the same active ingredient as Ozempic is a chemistry claim that leans on a brand's reputation. Saying a compounded sildenafil product is "clinically proven to improve outcomes in women with sexual arousal disorder" borrows the credibility of Viagra and then attaches it to a use and a population Viagra was never approved for. The word doing the work is "proven", and it is the one the letter disputes. If you are pricing a sexual-health product, that is the practical takeaway: a compounded formulation can share an ingredient with a famous drug and still be sold for something that drug was never shown to do. FDA is not saying either product is dangerous. It is saying that the strength of the evidence implied by "clinically proven" belonged to a different product, and that a shopper reading the page would not have known which.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Villas Health failed to respond.